[go: up one dir, main page]

SMT201200065B - Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina - Google Patents

Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina

Info

Publication number
SMT201200065B
SMT201200065B SM201200065T SM201200065T SMT201200065B SM T201200065 B SMT201200065 B SM T201200065B SM 201200065 T SM201200065 T SM 201200065T SM 201200065 T SM201200065 T SM 201200065T SM T201200065 B SMT201200065 B SM T201200065B
Authority
SM
San Marino
Prior art keywords
fluorophenoxymethyl
piperidine
phenyl
compound
crystalline form
Prior art date
Application number
SM201200065T
Other languages
English (en)
Italian (it)
Inventor
Lori Jean Patterson
Robert Chao
Miroslav Rapta
Original Assignee
Theravance Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41666409&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SMT201200065(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Theravance Inc filed Critical Theravance Inc
Publication of SMT201200065B publication Critical patent/SMT201200065B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
SM201200065T 2008-11-14 2012-12-28 Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina SMT201200065B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11454108P 2008-11-14 2008-11-14

Publications (1)

Publication Number Publication Date
SMT201200065B true SMT201200065B (it) 2013-03-08

Family

ID=41666409

Family Applications (3)

Application Number Title Priority Date Filing Date
SM201200063T SMT201200063B (it) 2008-11-14 2012-12-27 Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici
SM201200065T SMT201200065B (it) 2008-11-14 2012-12-28 Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina
SM201300033T SMT201300033B (it) 2008-11-14 2013-03-26 Procedimento per preparare composti della 4-[2-(2-fluorofenossimetil)fenil]piperidina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SM201200063T SMT201200063B (it) 2008-11-14 2012-12-27 Composti 4-[2-(-fluorofenossimetil)fenil]piperidinici

Family Applications After (1)

Application Number Title Priority Date Filing Date
SM201300033T SMT201300033B (it) 2008-11-14 2013-03-26 Procedimento per preparare composti della 4-[2-(2-fluorofenossimetil)fenil]piperidina

Country Status (28)

Country Link
US (23) US8247433B2 (xx)
EP (3) EP2358675B9 (xx)
JP (6) JP5598798B2 (xx)
KR (3) KR101685186B1 (xx)
CN (3) CN102216271B (xx)
AR (3) AR074128A1 (xx)
AU (3) AU2009313948B2 (xx)
BR (3) BRPI0921593B8 (xx)
CA (3) CA2739992C (xx)
CL (2) CL2011001088A1 (xx)
CO (2) CO6361988A2 (xx)
CY (3) CY1113622T1 (xx)
DK (3) DK2358676T3 (xx)
ES (3) ES2397247T3 (xx)
HR (3) HRP20120920T1 (xx)
IL (2) IL212230A (xx)
MX (3) MX2011005088A (xx)
MY (2) MY151211A (xx)
NZ (2) NZ592543A (xx)
PL (3) PL2358675T3 (xx)
PT (3) PT2358674E (xx)
RU (2) RU2503662C2 (xx)
SG (1) SG171311A1 (xx)
SI (3) SI2358676T1 (xx)
SM (3) SMT201200063B (xx)
TW (3) TWI461407B (xx)
WO (3) WO2010056941A1 (xx)
ZA (1) ZA201103495B (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2358675B9 (en) * 2008-11-14 2019-09-11 Theravance, Inc. 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
WO2011119461A1 (en) * 2010-03-22 2011-09-29 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
US20110263631A1 (en) * 2010-04-22 2011-10-27 Martin William J Combination of a serotonin and norepinephrine reuptake inhibitor and an opioid agonist for the treatment of pain
WO2012127506A1 (en) 2011-03-22 2012-09-27 Advinus Therapeutics Limited Substituted fused tricyclic compounds, compositions and medicinal applications thereof
US9544692B2 (en) * 2012-11-19 2017-01-10 Bitwave Pte Ltd. System and apparatus for boomless-microphone construction for wireless helmet communicator with siren signal detection and classification capability
FI3506900T3 (fi) * 2016-08-30 2024-11-29 Theravance Biopharma R&D Ip Llc Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension
US10640467B2 (en) 2018-06-01 2020-05-05 Theravance Biopharma R&D Ip, Llc Process for preparing 2-(1-(tert-butoxycarbonyl)piperidine-4-yl)benzoic acid
US20230372318A1 (en) 2022-03-28 2023-11-23 Theravance Biopharma R&D Ip, Llc Methods for treating a subject having multiple system atrophy
CN114957098B (zh) * 2022-06-02 2024-03-29 和鼎（南京）医药技术有限公司 一种制备喷他佐辛中间体的方法

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1422263A (en) * 1973-01-30 1976-01-21 Ferrosan As 4-phenyl-piperidine compounds
DE2549999A1 (de) 1975-11-07 1977-05-12 Boehringer Mannheim Gmbh Piperidin-derivate und verfahren zu ihrer herstellung
US4241071A (en) 1977-01-27 1980-12-23 American Hoechst Corporation Antidepressant (α-phenyl-2-tolyl)azacycloalkanes
IL56369A (en) 1978-01-20 1984-05-31 Erba Farmitalia Alpha-phenoxybenzyl propanolamine derivatives,their preparation and pharmaceutical compositions comprising them
US4198417A (en) * 1979-01-10 1980-04-15 American Hoechst Corporation Phenoxyphenylpiperidines
EP0190496A3 (en) 1984-12-13 1987-05-27 Beecham Group Plc Piperidine derivatives having a gastro-intestinal activity
US4956388A (en) * 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
DE3835291A1 (de) 1988-04-19 1989-11-02 Bayer Ag 1,3-disubstituierte pyrrolidine
GB9324018D0 (en) * 1993-11-23 1994-01-12 Merck Sharp & Dohme Therapeutic agents
BR9912013A (pt) * 1998-07-10 2001-04-10 Astrazeneca Ab Composto, composição farmacêutica, método de tratar uma condição de doença, e, processo para preparar um composto
GB9922521D0 (en) 1998-10-07 1999-11-24 Zeneca Ltd Compounds
US6518284B2 (en) 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
US6770666B2 (en) 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
WO2001047883A1 (fr) * 1999-12-27 2001-07-05 Japan Tobacco Inc. Composes a cycles accoles et leur utilisation comme medicaments
US6630504B2 (en) 2000-08-31 2003-10-07 Pfizer Inc. Phenoxyphenylheterocyclyl derivatives as SSRIs
US7294637B2 (en) 2000-09-11 2007-11-13 Sepracor, Inc. Method of treating addiction or dependence using a ligand for a monamine receptor or transporter
UA81749C2 (uk) 2001-10-04 2008-02-11 Х. Луннбек А/С Фенілпіперазинові похідні як інгібітори зворотного захоплення серотоніну
ATE413882T1 (de) 2002-08-23 2008-11-15 Lilly Co Eli 2-(phenylthiomethyl)- morpholin-derivate zur verwendung als selektive norepinephrin- wiederaufnahme-inhibitoren
CL2004000726A1 (es) * 2003-04-04 2005-05-20 Lundbeck & Co As H Compuestos derivados de 4-[2-(feniloxi sustituido)fenil]piperidina o -1,2,3,6-tetrahidropiridina; composcion farmaceutica que los contiene; y su uso para el tratamiento de trastornos afectivos, tales como la depresion, trastornos de ansiedad, de ansi
NZ540891A (en) 2003-04-04 2008-07-31 Lundbeck & Co As H 4-(2-Phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors
HRP20050993A2 (en) * 2003-06-17 2006-03-31 Pfizer Inc. N-pyrrolidin-3-yl-amide derivatives as serotonin and noradrenaline re-uptake inhibitors
TW200513461A (en) 2003-10-01 2005-04-16 Speedel Experimenta Ag Organische verbindungen
WO2005068447A1 (en) 2004-01-13 2005-07-28 Pfizer Limited Piperazine derivatives which exhibit activity as serotonin and noradrenaline re-upatke inhibitors
US20070072859A1 (en) * 2004-03-05 2007-03-29 Eli Lilly And Company Pharmaceutical compounds
BRPI0510453A (pt) 2004-04-30 2007-10-30 Warner Lambert Co composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central
GB0505437D0 (en) * 2005-03-17 2005-04-20 Merck Sharp & Dohme Therapeutic agents
US20070142389A1 (en) * 2005-12-20 2007-06-21 Pfizer Inc. Piperidine derivatives
US20070249607A1 (en) * 2006-04-17 2007-10-25 Bristol-Myers Squibb Company Nk-1 and serotonin transporter inhibitors
EP2066630A1 (en) 2006-08-23 2009-06-10 Pfizer Products Incorporated Piperidine derivatives
WO2008039418A2 (en) * 2006-09-27 2008-04-03 Merck & Co., Inc. Acylated piperidine derivatives as melanocortin-4 receptor modulators
US8026257B2 (en) * 2007-07-11 2011-09-27 Bristol-Myers Squibb Company Substituted heterocyclic ethers and their use in CNS disorders
WO2009081259A1 (en) 2007-12-21 2009-07-02 Pfizer Inc. Phenoxy-pyridyl derivatives
RU2010151352A (ru) 2008-06-20 2012-07-27 Метаболекс, Инк. (Us) Арильные агонисты grp119 и их применения
WO2010011811A2 (en) 2008-07-24 2010-01-28 Theravance, Inc. 3-(phenoxyphenylmethyl)pyrrolidine compounds
EP2358675B9 (en) 2008-11-14 2019-09-11 Theravance, Inc. 4-[2-(2-Fluorophenoxymethyl)phenyl]piperidine compounds
EP2523945A1 (en) 2010-01-11 2012-11-21 Theravance, Inc. 1 - (2 - phenoxymethylphenyl) piperazine compounds as serotonin and norepinephrine reuptake inhibitors
WO2011119461A1 (en) * 2010-03-22 2011-09-29 Theravance, Inc. 1-(2-phenoxymethylheteroaryl)piperidine and piperazine compounds
FI3506900T3 (fi) * 2016-08-30 2024-11-29 Theravance Biopharma R&D Ip Llc Ampreloksetiini käytettäväksi neurogeenisen ortostaattisen hypotension

Also Published As

Publication number Publication date
BRPI0921593B1 (pt) 2021-05-04
IL212452A0 (en) 2011-06-30
US11596624B2 (en) 2023-03-07
US20240316024A1 (en) 2024-09-26
TWI461407B (zh) 2014-11-21
NZ592413A (en) 2013-02-22
US8802857B2 (en) 2014-08-12
US20180055830A1 (en) 2018-03-01
ES2401224T3 (es) 2013-04-17
JP5598798B2 (ja) 2014-10-01
RU2515612C2 (ru) 2014-05-20
CN102216271A (zh) 2011-10-12
CY1113623T1 (el) 2016-06-22
US20230201181A1 (en) 2023-06-29
MX2011005090A (es) 2011-09-06
HRP20120897T1 (hr) 2012-12-31
MY151229A (en) 2014-04-30
US20120277438A1 (en) 2012-11-01
CA2742105C (en) 2016-09-13
JP5529150B2 (ja) 2014-06-25
CO6361993A2 (es) 2012-01-20
AR114965A2 (es) 2020-11-11
CY1113855T1 (el) 2016-07-27
CN102216271B (zh) 2013-09-25
US20190142816A1 (en) 2019-05-16
EP2358676B1 (en) 2012-10-10
MX2011005088A (es) 2011-06-01
US20100125092A1 (en) 2010-05-20
US20200316048A1 (en) 2020-10-08
US8304433B2 (en) 2012-11-06
CA2739992C (en) 2016-09-20
US20140323735A1 (en) 2014-10-30
EP2358674A1 (en) 2011-08-24
US20130030020A1 (en) 2013-01-31
CN102216272B (zh) 2014-02-05
CO6361988A2 (es) 2012-01-20
RU2011123875A (ru) 2012-12-20
US12239638B2 (en) 2025-03-04
PL2358675T3 (pl) 2013-03-29
US20180289687A1 (en) 2018-10-11
AU2009313948A1 (en) 2010-05-20
US11723900B2 (en) 2023-08-15
DK2358674T3 (da) 2013-04-08
US9162982B2 (en) 2015-10-20
DK2358675T3 (da) 2013-01-14
AR074350A1 (es) 2011-01-12
DK2358676T3 (da) 2013-01-14
AU2009313951B2 (en) 2015-03-12
CN102209712B (zh) 2016-04-06
US20200316047A1 (en) 2020-10-08
JP5506813B2 (ja) 2014-05-28
HK1160449A1 (en) 2012-08-17
US10946006B2 (en) 2021-03-16
ES2397247T3 (es) 2013-03-05
KR20110082085A (ko) 2011-07-15
KR101656339B1 (ko) 2016-09-09
BRPI0921595B8 (pt) 2021-05-25
IL212230A (en) 2014-12-31
SMT201200063B (it) 2013-01-14
US20100125141A1 (en) 2010-05-20
CA2742114A1 (en) 2010-05-20
AU2009313949B2 (en) 2015-03-19
CN102209712A (zh) 2011-10-05
CN102216272A (zh) 2011-10-12
HK1160452A1 (en) 2012-08-17
IL212230A0 (en) 2011-06-30
JP2012508759A (ja) 2012-04-12
US9187423B2 (en) 2015-11-17
KR101656338B1 (ko) 2016-09-09
HK1160448A1 (en) 2012-08-17
JP2012508760A (ja) 2012-04-12
US10576073B2 (en) 2020-03-03
EP2358674B1 (en) 2013-01-02
PT2358674E (pt) 2013-03-05
EP2358675B1 (en) 2012-10-03
TWI441810B (zh) 2014-06-21
US8592596B2 (en) 2013-11-26
CA2742105A1 (en) 2010-05-20
PL2358674T3 (pl) 2013-06-28
US20130030185A1 (en) 2013-01-31
US10946007B2 (en) 2021-03-16
PT2358676E (pt) 2012-12-06
US10722504B2 (en) 2020-07-28
KR20110082196A (ko) 2011-07-18
US10034870B2 (en) 2018-07-31
CL2011001088A1 (es) 2011-10-14
TW201024264A (en) 2010-07-01
US10226454B2 (en) 2019-03-12
US20160022660A1 (en) 2016-01-28
AU2009313948B2 (en) 2015-03-12
AR074128A1 (es) 2010-12-22
US20160184288A1 (en) 2016-06-30
US8247433B2 (en) 2012-08-21
BRPI0921596B1 (pt) 2021-10-26
ES2396583T3 (es) 2013-02-22
BRPI0921593A2 (pt) 2015-08-18
AU2009313949A1 (en) 2010-05-20
RU2503662C2 (ru) 2014-01-10
BRPI0921595B1 (pt) 2020-10-13
CA2742114C (en) 2016-09-13
HRP20120920T1 (hr) 2013-01-31
WO2010056939A1 (en) 2010-05-20
US9675599B2 (en) 2017-06-13
PL2358676T3 (pl) 2013-03-29
MY151211A (en) 2014-04-30
US20210290608A1 (en) 2021-09-23
JP2012508761A (ja) 2012-04-12
CL2011001093A1 (es) 2011-09-02
KR20110082197A (ko) 2011-07-18
CY1113622T1 (el) 2016-06-22
EP2358675A1 (en) 2011-08-24
US8604058B2 (en) 2013-12-10
US20190134019A1 (en) 2019-05-09
WO2010056938A1 (en) 2010-05-20
EP2358676A1 (en) 2011-08-24
US20140045892A1 (en) 2014-02-13
JP2014139209A (ja) 2014-07-31
ZA201103495B (en) 2012-01-25
TWI443087B (zh) 2014-07-01
JP2014101384A (ja) 2014-06-05
US10206913B2 (en) 2019-02-19
CA2739992A1 (en) 2010-05-20
WO2010056941A1 (en) 2010-05-20
KR101685186B1 (ko) 2016-12-09
BRPI0921593B8 (pt) 2021-05-25
NZ592543A (en) 2013-02-22
US20220087995A1 (en) 2022-03-24
MX2011005089A (es) 2011-07-29
SMT201300033B (it) 2013-05-06
HRP20130300T1 (hr) 2013-04-30
TW201022206A (en) 2010-06-16
AU2009313951A1 (en) 2010-05-20
PT2358675E (pt) 2012-12-12
EP2358675B9 (en) 2019-09-11
US20140057944A1 (en) 2014-02-27
SI2358675T1 (sl) 2013-01-31
BRPI0921596A2 (pt) 2018-03-20
RU2011123890A (ru) 2012-12-20
US20200000792A1 (en) 2020-01-02
US20100125093A1 (en) 2010-05-20
SI2358674T1 (sl) 2013-04-30
US9073859B2 (en) 2015-07-07
US10441579B2 (en) 2019-10-15
SI2358676T1 (sl) 2013-01-31
JP2014098033A (ja) 2014-05-29
SG171311A1 (en) 2011-07-28
US8304432B2 (en) 2012-11-06
US20180050024A1 (en) 2018-02-22
TW201024263A (en) 2010-07-01

Similar Documents

Publication Publication Date Title
SMT201200065B (it) Forma cristallina di un composto 4-[2-(2-fluorofenossimetil)fenil]piperidina
FR18C1020I2 (fr) Sels pharmaceutiquement acceptables de 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
SMT201400010B (it) Purificazione di 1-[2-(2,4-dimetilfenilsolfanil)fenilÜpiperazin a
RU2465270C3 (ru) Полиморфная форма 4-[3-(4-циклопропанкарбонилпиперазин-1-карбонил)-4-фторбензил]-2н-фталазин-1-она
EP2726075A4 (en) NEW CRYSTALLINE FORMS OF A DIPEPTIDYL-PEPTIDASE IV HEMMER
BRPI0915714A2 (pt) forma cristalina de posaconazol
BRPI0822398B8 (pt) forma sólida cristalina e composição farmacêutica que a compreende
DK2610258T3 (da) Substituerede piperidindihydrothienopyrimidiner
DOP2012000141A (es) Una forma amorfa y una cristalina de hemitartrato genz 112638 como inhibidor de glucosilceramida sintasa
SMT201600019B (it) Forma di base libera cristallina di un composto bifenilico
DK3564240T3 (da) Piperidinmellemprodukter
ATE506359T1 (de) Heteroaryl-substituierte piperidine
BRPI0817537A2 (pt) 4-[3-(4-ciclopropanocarbonil-piperazina-i-carboni-,-fl uoro-benzil]-2h-ftalazin-1-ona
SMT201600304B (it) Sale cloridrato di 4-[2-[[5-metil-1-(2- naftalenil]-1h-pirazol-3- il]ossi]etil]morfolina
ZA201003909B (en) Crystalline 2-(4-cyclopropanesulphonyl-phenyl)-n-pyrazin-2-yl-3-(tetrahydopyran-4-yl)-propionamide
PT2167085E (pt) Novas utilizações terapêuticas de 4-[2-(4- metilfenilsulfanil)fenil]piperidina
ATE479682T1 (de) Kristalline form einer chinolin-carboxamid- verbindung
DK2076494T3 (da) Piperidin- eller piperazinsubstituerede tetrahydro-naphthalen-1-carboxylsyre-mtp-inhiberende forbindelser
BRPI0816221A8 (pt) forma cristalina 1 da 2-((r)-2-metilpirrolidin-2-il)-1h-benzimidazol-4-carboxamida
IL200959A0 (en) Liquid formulations of salts of 4-[2-(4-methylphenylfanyl)phenyl]piperidine
IT1395453B1 (it) Assieme placca/controplacca di comando di una cassetta di risciacquo
BRPI0913396A2 (pt) compostos de piperidina 3- ou 4-substituídos
ITMI20042437A1 (it) Forma cristallina di rabeprazolo sodico
DK2181990T3 (da) Piperidinderivat
IT1393416B1 (it) Composizioni a base di nifedipina per trattamenti antirughe